Mayo Clinic Leverages Blockchain Technology for Clinical Trial Design
The company is looking to use Triall's medical software to create immutable clinical trial records.
New
On Thursday, Dutch blockchain startup Triall announced that it has partnered with US nonprofit medical center Mayo Clinic to optimize clinical trial design and study data management. Beginning in September, Triall's eClinical platform will support a two-year, multicenter pulmonary arterial hypertension clinical trial that includes 10 research sites and more than 500 patients across the United States.
The software will support activities such as data entry, document management, study tracking, and consent. As Triall said, the purpose of the collaboration is to demonstrate an immutable audit trail of the public ledger through its blockchain technology to strengthen the integrity of clinical trials. Investigators, regulators and stakeholders can then review and assess this trial-related data with confidence, knowing that no one can alter the records.
In the United States, the median cost of a clinical trial for new drugs or therapies is estimated at $19 million. Approval rates for new chemical entities and biologics typically hover between 10% and 20% from preclinical to completion and can often take years of investigation.
Launched in 2018, Triall released its first blockchain product, Verial eTMF. It allows researchers to generate verifiable evidence of the authenticity of clinical trial documents, such as patient diagnostic data. Additionally, the company is developing APIs through eClinical that allow existing third-party clinical trial software vendors to connect to Triall's blockchain infrastructure. The native TRL token is designed for ecosystem utility, such as paying compensation to clinical trial participants. If successful, Triall plans to continue its collaboration with the Mayo Clinic in the field of decentralized medical research.
The company is looking to use Triall's medical software to create immutable clinical trial records.
New
On Thursday, Dutch blockchain startup Triall announced that it has partnered with US nonprofit medical center Mayo Clinic to optimize clinical trial design and study data management. Beginning in September, Triall's eClinical platform will support a two-year, multicenter pulmonary arterial hypertension clinical trial that includes 10 research sites and more than 500 patients across the United States.
The software will support activities such as data entry, document management, study tracking, and consent. As Triall said, the purpose of the collaboration is to demonstrate an immutable audit trail of the public ledger through its blockchain technology to strengthen the integrity of clinical trials. Investigators, regulators and stakeholders can then review and assess this trial-related data with confidence, knowing that no one can alter the records.
In the United States, the median cost of a clinical trial for new drugs or therapies is estimated at $19 million. Approval rates for new chemical entities and biologics typically hover between 10% and 20% from preclinical to completion and can often take years of investigation.
Launched in 2018, Triall released its first blockchain product, Verial eTMF. It allows researchers to generate verifiable evidence of the authenticity of clinical trial documents, such as patient diagnostic data. Additionally, the company is developing APIs through eClinical that allow existing third-party clinical trial software vendors to connect to Triall's blockchain infrastructure. The native TRL token is designed for ecosystem utility, such as paying compensation to clinical trial participants. If successful, Triall plans to continue its collaboration with the Mayo Clinic in the field of decentralized medical research.
What's Your Reaction?
